The global gastroparesis treatment market reached US$ 7.5 billion in 2024 and is expected to reach US$ 11.03 billion by 2033, growing at a CAGR of 4.42% during the forecast period 2025-2033.
Gastroparesis is a chronic digestive condition characterized by delayed emptying of the stomach. It occurs when the stomach muscles or nerves are damaged, affecting their ability to contract and move food through the digestive tract effectively. This results in symptoms such as nausea, vomiting, bloating, and early satiety, which can significantly impact a patient’s quality of life.
Treatment options typically focus on alleviating symptoms and improving stomach function. These options include medications that enhance gastric motility, therapies aimed at controlling nausea and vomiting, and lifestyle changes like dietary modifications to make food easier to digest.
Market Dynamics: Drivers & Restraints
Advancements in Treatment Options
Advances in treatment options are playing a key role in driving the growth of the gastroparesis treatment market by introducing more effective and targeted solutions for patients. Over time, new prokinetic drugs, including updated versions of metoclopramide and domperidone, have emerged, offering better management of symptoms and improving gastric motility.
Additionally, alternative therapies such as botulinum toxin injections have provided new options for patients, particularly those with more severe symptoms. The companies are increasingly investing and receiving funds for introducing advancing treatment options that could drive market growth. For instance, CinDome Pharma has obtained $40 million in a Series B financing extension to advance the development of deudomperidone (CIN-102) for chronic gastroparesis. Existing investors, including Perceptive Advisors and CinRx Pharma, contributed to this investment
As these treatments continue to improve with fewer side effects and more individualized approaches, both healthcare providers and patients have access to better solutions for managing the condition. This expanded range of treatment options is expected to broaden the market, meeting the needs of a diverse patient population and driving demand across both developed and emerging markets.
Limited FDA-Approved Drugs
The limited number of FDA-approved drugs for gastroparesis restricts available treatment options, potentially hindering market growth. Currently, metoclopramide is the only drug approved by the FDA for gastroparesis treatment. Patients often rely on off-label drug uses or non-pharmaceutical treatments, which may be less effective. This lack of tailored options and approved therapies can lead to inadequate treatment outcomes for many patients.
Segment Analysis
The global gastroparesis treatment market is segmented based on gastroparesis type, drug class, route of administration, distribution channel, and region.
Drug Class:
Prokinetic drugs segment is expected to dominate the global gastroparesis treatment market share
The prokinetic drugs segment is expected to dominate the gastroparesis treatment market due to their proven ability to improve gastric motility, which is crucial for addressing delayed gastric emptying. Medications like metoclopramide and domperidone are commonly prescribed as first-line treatments, effectively alleviating symptoms such as nausea, bloating, and early satiety.
Moreover, continuous research and the development of more effective formulations with fewer side effects will fuel ongoing demand. For instance, in October 2024, Evoke Pharma, Inc., in collaboration with EVERSANA, presented data at the American College of Gastroenterology (ACG) 2024 Annual Meeting regarding the use of GIMOTI (metoclopramide) nasal spray for diabetic gastroparesis, particularly in GLP-1 users.
This dominance is further reinforced by the limited availability of alternative therapies, making prokinetic drugs the go-to option for many patients.
Geographical Analysis
North America is expected to hold a significant position in the global gastroparesis treatment market share
North America is expected to dominate the gastroparesis treatment market due to several factors. The region has a high frequency of diabetes and neurological issues, both of which are key risk factors for gastroparesis, resulting in a bigger patient population requiring effective treatment.
Furthermore, North America benefits from enhanced healthcare systems that enable early identification, cutting-edge therapies, and medications. The existence of major pharmaceutical companies, as well as ongoing research into new treatments, stimulates the market, as these companies are actively looking for creative solutions to gastroparesis. For instance, in October 2023, Avenacy launched and introduced thirteen injectable products to the U.S. market. Avenacy's Metoclopramide Injection, USP is available in 10 mg/2 mL single-dose vials and features specialized packaging and labeling for accurate medication selection. Their cost-effectiveness, especially when compared to more invasive treatments, ensures broader accessibility and widespread use, cementing prokinetic drugs as the foundation of gastroparesis treatment.
Competitive Landscape
The major global players in the gastroparesis treatment market include Conmed Corporation, The Cooper Companies Inc, Teleflex Incorporated, Medtronic Plc, B. Braun Medical Inc, JOHNSON & JOHNSON, Laprosurge, Purple Surgical, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and Peters Surgical among others.
Key Developments
• In June 2024, Renexxion Ireland Ltd., a biopharmaceutical company focused on GI disorders, received FDA clearance for its Investigational New Drug (IND) application for naronapride to treat gastroparesis. Naronapride, a potential best-in-class oral prokinetic agent, modulates 5-HT4 receptor agonism and D2 receptor antagonism.
Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The Global Gastroparesis Treatment Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Gastroparesis Type
- 3.2. Snippet by Drug Class
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rising Prevalence of Chronic Diseases
- 4.1.2. Restraints
- 4.1.2.1. Risk of Complications
- 4.1.3. Opportunity
- 4.2. Impact Analysis
- 5. Strategic Insights and Industry Outlook
- 5.1. Market Leaders and Pioneers
- 5.1.1. Emerging Pioneers and Prominent Players
- 5.1.2. Established leaders with largest selling Brand
- 5.1.3. Market leaders with established Product
- 5.2. CXO Perspectives
- 5.3. Latest Developments and Breakthroughs
- 5.4. Case Studies/Ongoing Research
- 5.5. Regulatory and Reimbursement Landscape
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 5.6. Porter’s Five Force Analysis
- 5.7. Supply Chain Analysis
- 5.8. Patent Analysis
- 5.9. SWOT Analysis
- 5.10. Unmet Needs and Gaps
- 5.11. Recommended Strategies for Market Entry and Expansion
- 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 5.13. Pricing Analysis and Price Dynamics
- 5.14. Key Opinion Leaders
- 6. By Gastroparesis Type
- 6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Gastroparesis Type
- 6.1.2. Market Attractiveness Index, By Gastroparesis Type
- 6.2. Idiopathic Gastroparesis*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Diabetic Gastroparesis
- 6.4. Post-surgical Gastroparesis
- 7. By Drug Class
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 7.1.2. Market Attractiveness Index, By Drug Class
- 7.2. Prokinetic Drugs*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Antiemetics
- 7.4. Antidepressants
- 7.5. Liquid Vitamin Supplements
- 7.6. Others
- 8. By Route of Administration
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Oral*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Injectables
- 8.4. Others
- 9. By Distribution Channel
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital Pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Retail Pharmacies
- 9.4. Online Pharmacies
- 10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gastroparesis Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.7.1. U.S.
- 10.2.7.2. Canada
- 10.2.7.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gastroparesis Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.7.1. Germany
- 10.3.7.2. U.K.
- 10.3.7.3. France
- 10.3.7.4. Spain
- 10.3.7.5. Italy
- 10.3.7.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gastroparesis Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.7.1. Brazil
- 10.4.7.2. Argentina
- 10.4.7.3. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gastroparesis Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.7.1. China
- 10.5.7.2. India
- 10.5.7.3. Japan
- 10.5.7.4. South Korea
- 10.5.7.5. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gastroparesis Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
- 12. Company Profiles
- Key Market Players
- 12.1. Pfizer Inc.*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio
- 12.1.2.1. Product Description
- 12.1.2.2. Product Key Performance Indicators (KPIs)
- 12.1.2.3. Historic and Forecasted Product Sales
- 12.1.2.4. Product Sales Volume
- 12.1.3. Financial Overview
- 12.1.3.1. Company Revenue’s
- 12.1.3.2. Geographical Revenue Shares
- 12.1.3.3. Revenue Forecasts
- 12.1.4. Key Developments
- 12.1.4.1. Mergers & Acquisitions
- 12.1.4.2. Key Product Development Activities
- 12.1.4.3. Regulatory Approvals etc.
- 12.1.5. SWOT Analysis
- 12.2. AdvaCare Pharma
- 12.3. Theravance Biopharma
- 12.4. Wellona Pharma
- 12.5. EVOKE PHARMA
- * Similar data will be provided for each market player.
- Emerging Market Players
- 12.6. Neurogastrx, Inc.*
- 12.6.1. Pipeline Products Description
- 12.6.2. Product Key Performance Indicators (KPIs)
- 12.6.3. Key Activities
- 12.6.4. Market Entry Timelines
- 12.6.5. Product Penetration Rate
- 12.6.6. Sales Estimation and Projections
- 12.7. Processa Pharmaceuticals, Inc.
- 12.8. Vanda Pharmaceuticals Inc.
- 12.9. Dr. Falk Pharma GmbH
- 12.10. Aclipse Therapeutics
- * Similar data will be provided for each market player.
- LIST NOT EXHAUSTIVE
- 13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook